The company’s proprietary technology TRACT (Tissue Regenerative Activated Cell Therapy) is based on an unprecedented combination of the power of immunology and stem cell therapy providing personalized regenerative treatment for damaged tissues. The leading product BGC 101, is a highly innovative autologous cell therapy that is being studied in clinical programs in patients with chronic limb-threatening ischemia (CLI), a poorly treated disease with a high risk of amputation and death.
BGC- 101 has been shown to be both safe and effective, alleviating CLI in the majority of patients, offering the potential to reduce the need for amputation and increase the quality of life of CLI patients. BioGenCell is developing BGC-101 in a range of other indications and, pending approval, intends to launch and market this specialty product in all major territories.
BioGenCell is a privately-owned company, which draws on an exceptional understanding of the fundamental science of autologous cell therapies developed over the last decade.
The Company was founded in 2008 and is headquartered in Tel Aviv, Israel with a European Operations in Belgium.
To read more People News articles, click here.